News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – April

OIS Dry Eye Innovation Showcase Presentation

Axitinib Implant (AR-14034) Overview

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 19, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 7, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 30, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 11, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP